RU2005141559A - Способ лечения и предотвращения симптомов нижнего отдела мочевых путей - Google Patents
Способ лечения и предотвращения симптомов нижнего отдела мочевых путей Download PDFInfo
- Publication number
- RU2005141559A RU2005141559A RU2005141559/14A RU2005141559A RU2005141559A RU 2005141559 A RU2005141559 A RU 2005141559A RU 2005141559/14 A RU2005141559/14 A RU 2005141559/14A RU 2005141559 A RU2005141559 A RU 2005141559A RU 2005141559 A RU2005141559 A RU 2005141559A
- Authority
- RU
- Russia
- Prior art keywords
- enyl
- chloro
- symptoms
- individuals
- urinary tract
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
- A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (22)
1. Применение селективного модулятора эстрогенных рецепторов или его изомера, смеси изомеров или его фармацевтически приемлемой соли для приготовления фармацевтической композиции, для лечения или предотвращения симптомов нижнего отдела мочевых путей с или без тазовой боли у индивидуума.
2. Применение по п.1, где симптомы нижнего отдела мочевых путей представляют собой диссинергию мочевого пузыря/уретры, диссинергию шейки мочевого пузыря или синдром Хинмана у индивидуумов мужского пола.
3. Применение по п.1, где симптомы нижнего отдела мочевых путей представляют собой неотложный позыв к мочеиспусканию у индивидуумов женского пола.
4. Применение по п.1, где симптомы нижнего отдела мочевых путей представляют собой абактериальный простатит, стрессовый простатит, тригонит или орхиалгию у индивидуумов мужского пола.
5. Применение по п.1, где симптомы нижнего отдела мочевых путей представляют собой нестабильность мочевого пузыря или интерстициальный цистит у индивидуумов мужского или женского пола.
6. Применение по п.1, где тазовая боль связана с абактериальным простатитом, стрессовым простатитом, простатодинией, уретральными синдромами, тригонитом или орхиалгией индивидуумов мужского пола.
7. Применение по п.1, где тазовая боль представляет собой интерстициальный цистит у индивидуумов мужского или женского пола.
8. Применение по п.1, где селективный модулятор эстрогенных рецепторов представляет собой трифенилалкеновое соединение, трифенилалкановое соединение, бензотиофеновое соединение, ЕМ652, ЕМ800, ЕМ776, ЕМ651, ЕМ312, ICI 182780, ERA-923, циндоксифен, деацетилированный циндоксифен, ZK119010, TSE-4247, лазоксифен, аналоги лазоксифена, нафоксидин, базедоксифен, GW5638, GW7604, ICI 164384, RU 58668, RU 39411 или EM 319.
9. Применение по п.1, где селективный модулятор эстрогенных рецепторов представляет собой соединение с низкой эстрогенной активностью или не имеющее эстрогенной активности
10. Применение по п.9, где селективный модулятор эстрогенных рецепторов выбран из группы, содержащей
(Z)-2-[3-(4-хлор-1,2-дифенилбут-1-енил)фенокси}этанол;
(Z)-2-{2-[4-(4-хлор-1,2-дифенилбут-1-енил)фенокси]этокси}этанол (фиспемифен);
(Z)-{2-[3-(4-хлор-1,2-дифенилбут-1-енил)фенокси]этил}диметиламин;
(Е)-3-{4-хлор-1-[4-(2-гидроксиэтокси)фенил]-2-фенилбут-1-енил}фенол;
(Е)-3-{4-хлор-1-[4-(2-имидазол-1-илэтокси)фенил]-2-фенилбут-1-енил}фенол;
(Z)-3-{4-хлор-1-[4-(2-имидазол-1-илэтокси)фенил]-2-фенилбут-1-енил}фенол; или
ралоксифен,
или их любой изомер, смесь изомеров или фармацевтически приемлемую соль.
11. Применение по п.9, где селективный модулятор эстрогенных рецепторов представляет собой фиспемифен.
12. Способ лечения или предотвращения у индивидуума симптомов нижнего отдела мочевых путей с тазовой болью или без нее, причем указанный способ включает введение индивидууму эффективного количества селективного модулятора эстрогенных рецепторов или его изомера, смеси изомеров или фармацевтически приемлемой соли.
13. Способ по п.12, где симптомы нижнего отдела мочевых путей представляют собой диссинергию мочевого пузыря/уретры, диссинергию шейки мочевого пузыря или синдром Хинмана у индивидуумов мужского пола.
14. Способ по п.12, где симптомы нижнего отдела мочевых путей представляют собой неотложный позыв к мочеиспусканию у индивидуумов женского пола.
15. Способ по п.12, где симптомы нижнего отдела мочевых путей представляют собой абактериальный простатит, стрессовый простатит, тригонит или орхиалгию у индивидуумов мужского пола.
16. Способ по п.12, где симптомы нижнего отдела мочевых путей представляют собой нестабильность мочевого пузыря или интерстициальный цистит у индивидуумов мужского или женского пола.
17. Способ по п.12, где тазовая боль связана с абактериальным простатитом, стрессовым простатитом, простатодинией, уретральными синдромами, тригонитом или орхиалгией у индивидуумов мужского пола.
18. Способ по п.12, где тазовая боль представляет собой интерстициальный цистит индивидуумов мужского или женского пола.
19. Способ по п.12, где селективный модулятор эстрогенных рецепторов представляет собой трифенилалкеновое соединение, трифенилалкановое соединение, бензотиофеновое соединение, ЕМ652, ЕМ800, ЕМ776, ЕМ651, ЕМ312, ICI 182780, ERA-923, циндоксифен, деацетилированный циндоксифен, ZK119010, TSE-4247, лазоксифен, аналоги лазоксифена, нафоксидин, базедоксифен, GW5638, GW7604, ICI 164384, RU 58668, RU 39411 или EM 319.
20. Способ по п.12, где селективный модулятор эстрогенных рецепторов представляет собой соединение с низкой эстрогенной активностью или не имеющее эстрогенной активности.
21. Способ по п.20, где селективный модулятор эстрогенных рецепторов выбран из группы, содержащей
(Z)-2-[3-(4-хлор-1,2-дифенилбут-1-енил)фенокси}этанол;
(Z)-2-{2-[4-(4-хлор-1,2-дифенилбут-1-енил)фенокси]этокси}этанол (фиспемифен);
(Z)-{2-[3-(4-хлор-1,2-дифенилбут-1-енил)фенокси]этил}диметиламин;
(Е)-3-{4-хлор-1-[4-(2-гидроксиэтокси)фенил]-2-фенилбут-1-енил}фенол;
(Е)-3-{4-хлор-1-[4-(2-имидазол-1-илэтокси)фенил]-2-фенилбут-1-енил}фенол;
(Z)-3-{4-хлор-1-[4-(2-имидазол-1-илэтокси)фенил]-2-фенилбут-1-енил}фенол, или
ралоксифен.
или их любой изомер, смесь изомеров или фармацевтически приемлемую соль.
22. Способ по п.20, где селективный модулятор эстрогенных рецепторов представляет собой фиспемифен.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/454,823 | 2003-06-05 | ||
US10/454,823 US20040248989A1 (en) | 2003-06-05 | 2003-06-05 | Method for the treatment or prevention of lower urinary tract symptoms |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2005141559A true RU2005141559A (ru) | 2006-06-10 |
Family
ID=33489800
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2005141559/14A RU2005141559A (ru) | 2003-06-05 | 2004-05-05 | Способ лечения и предотвращения симптомов нижнего отдела мочевых путей |
Country Status (13)
Country | Link |
---|---|
US (6) | US20040248989A1 (ru) |
EP (2) | EP1636159B1 (ru) |
JP (1) | JP4731470B2 (ru) |
KR (1) | KR20060016763A (ru) |
CN (1) | CN100526277C (ru) |
AU (2) | AU2004245251B2 (ru) |
CA (1) | CA2527396C (ru) |
ES (1) | ES2524575T3 (ru) |
IS (1) | IS2958B (ru) |
MX (1) | MXPA05013104A (ru) |
NO (1) | NO337660B1 (ru) |
RU (1) | RU2005141559A (ru) |
WO (1) | WO2004108645A1 (ru) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040248989A1 (en) | 2003-06-05 | 2004-12-09 | Risto Santti | Method for the treatment or prevention of lower urinary tract symptoms |
EP1948148A2 (en) * | 2005-11-09 | 2008-07-30 | Hormos Medical Ltd. | Formulations of fispemifene |
WO2007135547A2 (en) * | 2006-05-22 | 2007-11-29 | Hormos Medical Ltd. | Selective estrogen receptor modulators or aromatase inhibitors for treating chronic nonbacterial prostatitis |
ES2590262T3 (es) | 2007-02-14 | 2016-11-21 | Hormos Medical Ltd. | Método para la preparación de derivados de trifenilbuteno con valor terapéutico |
US7504530B2 (en) * | 2007-02-14 | 2009-03-17 | Hormos Medical Ltd. | Methods for the preparation of fispemifene from ospemifene |
HUE033581T2 (hu) | 2010-06-10 | 2017-12-28 | Seragon Pharmaceuticals Inc | Ösztrogén receptor modulátorok és alkalmazásaik |
CA2857057A1 (en) | 2011-12-14 | 2013-06-20 | Seragon Pharmaceuticals, Inc. | Fluorinated estrogen receptor modulators and uses thereof |
CN102716106A (zh) * | 2012-06-20 | 2012-10-10 | 中国农业大学 | 他昔莫芬的新用途 |
US9321712B2 (en) | 2012-10-19 | 2016-04-26 | Fermion Oy | Process for the preparation of ospemifene |
RU2552922C1 (ru) * | 2014-07-04 | 2015-06-10 | Федеральное государственное бюджетное учреждение "Новосибирский научно-исследовательский институт туберкулеза" Министерства здравоохранения Российской Федерации (ФГБУ "ННИИТ" Минздрава России) | Способ лечения хронического абактериального простатита, осложненного сексуальной дисфункцией |
US9975832B2 (en) | 2014-12-29 | 2018-05-22 | Olon S.P.A. | Process for the preparation of ospemifene and fispemifene |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE637389A (ru) | 1962-09-13 | |||
US4133814A (en) | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
US4418068A (en) | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
US4656187A (en) * | 1981-08-03 | 1987-04-07 | Eli Lilly And Company | Treatment of mammary cancer |
GB2126576B (en) * | 1982-06-25 | 1985-06-19 | Farmos Group Limited | Alkane and alkene derivatives |
FI77839C (fi) | 1982-05-27 | 1989-05-10 | Farmos Oy | Foerfarande foer framstaellning av nya terapeutiskt effektiva trifenylalkan- och alkenderivat. |
US5491173A (en) * | 1982-06-25 | 1996-02-13 | Orion-Yhtyma Oy | Tri-phenyl alkene derivatives and their preparation and use |
US4729999A (en) * | 1984-10-12 | 1988-03-08 | Bcm Technologies | Antiestrogen therapy for symptoms of estrogen deficiency |
DE3762617D1 (de) * | 1986-09-11 | 1990-06-13 | Nat Res Dev | Tamoxifenderivate. |
US4977906A (en) * | 1989-03-07 | 1990-12-18 | Scipio William J Di | Diurnal rehabilitation for incontinence trainer |
US5189212A (en) * | 1990-09-07 | 1993-02-23 | University Of Georgia Research Foundation, Inc. | Triarylethylene carboxylic acids with estrogenic activity |
EP0551434B1 (en) | 1990-10-01 | 1995-11-15 | The Board Of Regents, The University Of Texas System | High affinity tamoxifen derivatives and uses thereof |
US6096874A (en) | 1990-10-01 | 2000-08-01 | Board Of Regents, The University Of Texas System | High affinity tamoxifen derivatives |
US5219548A (en) * | 1990-10-01 | 1993-06-15 | Board Of Regents, The University Of Texas System | High affinity halogenated-tamoxifen derivatives and uses thereof |
US5118667A (en) * | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
US5196435A (en) * | 1991-11-21 | 1993-03-23 | Eli Lilly And Company | Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma |
GB9207437D0 (en) | 1992-04-03 | 1992-05-20 | Orion Yhtymae Oy | Topical administration of toremifene and its metabolites |
TW366342B (en) | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
US5446203A (en) * | 1992-08-25 | 1995-08-29 | New York University | Synthesis of haloenones and aryl or alkyl substituted enones or alkenes |
GB2273704B (en) | 1992-12-16 | 1997-01-22 | Orion Yhtymae Oy | Triazolyl diaryl selective aromatase inhibiting compounds |
DE4335876A1 (de) * | 1993-10-17 | 1995-04-20 | Schering Ag | Kombination von Progesteronantagonisten und Antiöstrogenen mit partialer agonistischer Wirkung für die Hormonsubstitutions-Therapie für peri- und postmenopausale Frauen |
US5650425A (en) | 1994-04-04 | 1997-07-22 | Pharmos Corporation | Permanently ionic derivatives of steroid hormones and their antagonists |
US5681835A (en) * | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
US5604248A (en) * | 1994-05-05 | 1997-02-18 | Eli Lilly And Company | Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs |
US5470883A (en) * | 1994-05-23 | 1995-11-28 | Stromberg; Brent V. | Method of treating peripheral vasoconstriction with tamoxifen citrate |
US5441986A (en) * | 1994-07-19 | 1995-08-15 | Pfizer Inc. | Estrogen agonists as remedies for prostate and cardiovascular diseases |
GB9418067D0 (en) * | 1994-09-07 | 1994-10-26 | Orion Yhtymae Oy | Triphenylethylenes for the prevention and treatment of osteoporosis |
US5658931A (en) * | 1994-09-20 | 1997-08-19 | Eli Lilly And Company | Method for inhibiting mammalian breast carcinoma with tamoxifen, and analogs thereof, and certain naphthyl compounds |
DE4435368A1 (de) * | 1994-09-22 | 1996-03-28 | Schering Ag | Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann |
MX9703944A (es) * | 1994-11-29 | 1998-05-31 | Hoechst Marion Roussel Inc | Metodo para usar derivados de triaril-etileno en el tratamiento y prevencion de osteoporosis. |
US5552412A (en) | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
US5821254A (en) * | 1995-02-17 | 1998-10-13 | The United States Of America As Represented By The Department Of Health And Human Services | Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer |
GB9509572D0 (en) | 1995-05-11 | 1995-07-05 | Cancer Res Campaign Tech | Cancer therapy |
US6262115B1 (en) * | 1995-05-22 | 2001-07-17 | Alza Coporation | Method for the management of incontinence |
DE19526146A1 (de) * | 1995-07-07 | 1997-01-09 | Schering Ag | Triphenylethylene, Verfahren zu deren Herstellung, diese Triphenylethylene enthaltene pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln |
JP2000503991A (ja) * | 1996-01-29 | 2000-04-04 | イーライ・リリー・アンド・カンパニー | 括約筋受容能力を増大させる方法 |
GB9604577D0 (en) * | 1996-03-04 | 1996-05-01 | Orion Yhtymae Oy | Serum cholesterol lowering agent |
WO1998011888A1 (en) * | 1996-09-19 | 1998-03-26 | American Home Products Corporation | Method of treating urinary incontinence |
US5972921A (en) * | 1997-12-12 | 1999-10-26 | Hormos Medical Oy Ltd. | Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men |
GB9803521D0 (en) | 1998-02-19 | 1998-04-15 | Orion Yhtymo Oy | New compounds and pharmaceutical compositions thereof |
US6465445B1 (en) | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
WO1999066915A2 (en) * | 1998-06-23 | 1999-12-29 | Southern Illinois University At Carbondale | Therapeutic applications of estrogenic carboxylic acids |
EP1004306A3 (en) * | 1998-08-06 | 2000-06-07 | Pfizer Products Inc. | Estrogen agonists/antagonists |
JP2003521468A (ja) * | 1999-03-17 | 2003-07-15 | シグナル ファーマシューティカルズ, インコーポレイテッド | エストロゲンレセプタを変調させるための化合物及び方法 |
TW593256B (en) * | 1999-11-16 | 2004-06-21 | Hormos Medical Oy Ltd | Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
GB0015246D0 (en) * | 2000-06-22 | 2000-08-16 | Astrazeneca Ab | Method for the treatment of urinary incontinence |
AU2001271781A1 (en) * | 2000-07-06 | 2002-01-21 | Wyeth | Use of substituted indole compounds for treating sphincter incontinence |
US6245819B1 (en) * | 2000-07-21 | 2001-06-12 | Hormos Medical Oy, Ltd. | Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause |
IL145838A (en) * | 2000-10-16 | 2008-11-03 | Pfizer Prod Inc | Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis |
GB0030037D0 (en) | 2000-12-08 | 2001-01-24 | Karobio Ab | Novel estrogen receptor ligands and methods III |
FI111710B (fi) * | 2001-05-04 | 2003-09-15 | Hormos Medical Oy Ltd | Menetelmä terapeuttisesti aktiivisen yhdisteen valmistamiseksi |
MXPA04003866A (es) * | 2001-11-09 | 2004-07-08 | Pharmacia Ab | Agente-antimuscarnico y agonista de estrogeno para tratar la vejiga inestable o hiperactiva. |
AU2003247608A1 (en) * | 2002-06-25 | 2004-01-06 | Wyeth | Use of cyclothiocarbamate derivatives in treatment of hormone-related conditions |
US20040248989A1 (en) | 2003-06-05 | 2004-12-09 | Risto Santti | Method for the treatment or prevention of lower urinary tract symptoms |
WO2007135547A2 (en) * | 2006-05-22 | 2007-11-29 | Hormos Medical Ltd. | Selective estrogen receptor modulators or aromatase inhibitors for treating chronic nonbacterial prostatitis |
-
2003
- 2003-06-05 US US10/454,823 patent/US20040248989A1/en not_active Abandoned
-
2004
- 2004-05-05 KR KR20057020641A patent/KR20060016763A/ko not_active Application Discontinuation
- 2004-05-05 EP EP04731197.2A patent/EP1636159B1/en not_active Expired - Lifetime
- 2004-05-05 CN CNB2004800152437A patent/CN100526277C/zh not_active Expired - Fee Related
- 2004-05-05 RU RU2005141559/14A patent/RU2005141559A/ru not_active Application Discontinuation
- 2004-05-05 ES ES04731197.2T patent/ES2524575T3/es not_active Expired - Lifetime
- 2004-05-05 WO PCT/FI2004/000270 patent/WO2004108645A1/en active Application Filing
- 2004-05-05 EP EP20100180610 patent/EP2258360A3/en not_active Withdrawn
- 2004-05-05 JP JP2006508325A patent/JP4731470B2/ja not_active Expired - Fee Related
- 2004-05-05 MX MXPA05013104A patent/MXPA05013104A/es active IP Right Grant
- 2004-05-05 AU AU2004245251A patent/AU2004245251B2/en not_active Ceased
- 2004-05-05 CA CA 2527396 patent/CA2527396C/en not_active Expired - Lifetime
-
2005
- 2005-11-04 NO NO20055187A patent/NO337660B1/no not_active IP Right Cessation
- 2005-12-01 IS IS8162A patent/IS2958B/is unknown
-
2010
- 2010-08-16 US US12/856,738 patent/US20100305158A1/en not_active Abandoned
- 2010-12-23 AU AU2010257419A patent/AU2010257419B2/en not_active Ceased
-
2013
- 2013-08-19 US US13/970,026 patent/US8962693B2/en not_active Expired - Fee Related
-
2015
- 2015-01-15 US US14/597,453 patent/US9114106B2/en not_active Expired - Fee Related
- 2015-08-21 US US14/832,649 patent/US9993442B2/en not_active Expired - Lifetime
-
2018
- 2018-05-08 US US15/973,783 patent/US10780063B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US10780063B2 (en) | 2020-09-22 |
US8962693B2 (en) | 2015-02-24 |
IS8162A (is) | 2005-12-01 |
JP2006526595A (ja) | 2006-11-24 |
NO20055187D0 (no) | 2005-11-04 |
US9993442B2 (en) | 2018-06-12 |
MXPA05013104A (es) | 2006-03-17 |
CA2527396C (en) | 2012-10-16 |
US20150126613A1 (en) | 2015-05-07 |
CA2527396A1 (en) | 2004-12-16 |
KR20060016763A (ko) | 2006-02-22 |
ES2524575T3 (es) | 2014-12-10 |
NO20055187L (no) | 2005-12-19 |
US9114106B2 (en) | 2015-08-25 |
AU2010257419B2 (en) | 2011-06-23 |
US20180256513A1 (en) | 2018-09-13 |
NO337660B1 (no) | 2016-05-30 |
CN100526277C (zh) | 2009-08-12 |
AU2004245251B2 (en) | 2010-10-07 |
JP4731470B2 (ja) | 2011-07-27 |
US20100305158A1 (en) | 2010-12-02 |
CN1798723A (zh) | 2006-07-05 |
AU2004245251A1 (en) | 2004-12-16 |
US20130345313A1 (en) | 2013-12-26 |
IS2958B (is) | 2017-02-15 |
EP1636159B1 (en) | 2014-09-24 |
EP1636159A1 (en) | 2006-03-22 |
EP2258360A2 (en) | 2010-12-08 |
WO2004108645A1 (en) | 2004-12-16 |
US20150352059A1 (en) | 2015-12-10 |
EP2258360A3 (en) | 2011-03-23 |
AU2010257419A1 (en) | 2011-01-20 |
US20040248989A1 (en) | 2004-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI359015B (en) | Pharmaceutical composition for treatment or preve | |
RU2005141559A (ru) | Способ лечения и предотвращения симптомов нижнего отдела мочевых путей | |
Robertson | ICI 182,780 (Fulvestrant™)–the first oestrogen receptor down-regulator–current clinical data | |
MX2019007772A (es) | Precursores esteroides sexuales solos o en combinacion con un modulador receptor de estrogeno selectivo y/o con estrogenos y/o con un inhibidor de fosfodiesterasa gmpc de tipo 5 para la prevencion y tratamiento de sequedad vaginal y disfuncion sexual en mujeres post-menopausicas. | |
CA2654798C (en) | Flibanserin for the treatment of urinary incontinence and related diseases | |
Morales et al. | A review of the current status of topical treatments for premature ejaculation | |
JP2004507465A5 (ru) | ||
AU2005202257C1 (en) | Azacyclic compounds for use in the treatment of serotonin related diseases | |
JP2001517639A (ja) | 鼻炎/結膜炎および感冒、感冒に似た症状および/または流行性感冒の症状を局所的に治療するための、鎮静作用を有しない抗ヒスタミンおよびα−アドレナリン作動薬を含む組合せ物の使用 | |
CN1222283C (zh) | 利用快速起效的选择性5-羟色胺再摄取抑制剂来治疗性功能障碍的方法 | |
KR20060109912A (ko) | Dpp ⅳ 억제제와 항비만제 또는 식욕 조절제의 조합물 | |
EP1397126B1 (en) | Use of tramadol for delaying ejaculation | |
JPH10511962A (ja) | 婦人科疾患の治療または予防用の医薬組成物の製造への3,4−ジフェニルクロマンの使用 | |
AU735617B2 (en) | Estrogen agonist/antagonists treatment of atherosclerosis | |
JP2004521951A5 (ru) | ||
ES2260910T3 (es) | Metodos y composiciones que utilizan metabolitos de terfenadina en combinacion con inhibidores de leucotrienos. | |
RU2332989C2 (ru) | Способ получения 1r,2s-метоксамина, его терапевтическое применение (варианты) и фармацевтическая композиция | |
Polimeni et al. | Venlafaxine-induced urinary incontinence resolved after switching to sertraline | |
EA010868B1 (ru) | Применение производных бицикло[2.2.1]гептана для приготовления нейропротекторных фармацевтических композиций | |
HU206976B (en) | Process for producing pharmaceutical compositions comprising naphthopydil, for treating diuria | |
WO1998000141A1 (en) | Methods and compositions for treating urinary incontinence using enantiomerically enriched (s)-trihexyphenidyl | |
JPH08231397A (ja) | 喫煙関連性骨損失治療用製剤 | |
JP2002532546A (ja) | 乳癌についての内分泌治療:抗エストロゲンおよびアルキルpcdfを用いる組合せ処置 | |
NO20072687L (no) | Farmasoytisk prevensjonspreparat | |
Sorbera et al. | Pipendoxifene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20090119 |